U.S. FDA Advisers Back Safety Of GRAIL's Galleri Multi-Cancer Screening Test; FDA Advisers Vote 6-4 That GRAIL's Galleri Is Effective For Proposed Use In Multi-Cancer Screening Test; Advisers Vote 7-2, With One Abstention, That Benefits Of GRAIL's Galleri Test Outweigh Risks For Proposed Use

U.S. FDA advisers have voted 6-4 in favor of the effectiveness of GRAIL's Galleri multi-cancer screening test for its proposed use. Additionally, the advisers voted 7-2, with one abstention, indicating that the benefits of the Galleri test outweigh its risks. This endorsement could impact GRAIL's market position and stock performance, particularly for ticker GRAL.